Renal Cell Cancer, Recurrent Completed Phase 2 Trials for Thalidomide (DB01041)

Also known as: Recurrent Renal Cell Cancer

IndicationStatusPhase
DBCOND0082537 (Renal Cell Cancer, Recurrent)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00019539Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney CancerTreatment